BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 22381138)

  • 1. Histology-specific long-term trends in the incidence of ovarian cancer and borderline tumor in Japanese females: a population-based study from 1983 to 2007 in Niigata.
    Yahata T; Banzai C; Tanaka K;
    J Obstet Gynaecol Res; 2012 Apr; 38(4):645-50. PubMed ID: 22381138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian cancer incidence in the United States, 1992-1999.
    Quirk JT; Natarajan N
    Gynecol Oncol; 2005 May; 97(2):519-23. PubMed ID: 15863154
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian cancer histology-specific incidence trends in Canada 1969-1993: age-period-cohort analyses.
    Zhang J; Ugnat AM; Clarke K; Mao Y
    Br J Cancer; 1999 Sep; 81(1):152-8. PubMed ID: 10487627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ovarian cancer and borderline tumors].
    Bjørge T; Engeland A; Hansen S; Tropé CG
    Tidsskr Nor Laegeforen; 1998 Jun; 118(16):2471-5. PubMed ID: 9667122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
    Jordan SJ; Green AC; Whiteman DC; Webb PM;
    Gynecol Oncol; 2007 Nov; 107(2):223-30. PubMed ID: 17662378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cigarette smoking and risk of epithelial ovarian cancer.
    Rossing MA; Cushing-Haugen KL; Wicklund KG; Weiss NS
    Cancer Causes Control; 2008 May; 19(4):413-20. PubMed ID: 18080774
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased risk of second cancer among patients with ovarian borderline tumors.
    Bouchardy C; Fernandez S; Merglen A; Usel M; Fioretta G; Rapiti E; Schubert H; Pelte MF; Chappuis PO; Vlastos G
    Gynecol Oncol; 2008 May; 109(2):210-4. PubMed ID: 18377966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in the mortality (1950-1997) and incidence (1975-1993) of malignant ovarian neoplasm among Japanese women: analyses by age, time, and birth cohort.
    Tamakoshi K; Kondo T; Yatsuya H; Hori Y; Kikkawa F; Toyoshima H
    Gynecol Oncol; 2001 Oct; 83(1):64-71. PubMed ID: 11585415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Declining trends of epithelial ovarian cancer in California.
    Morris CR; Rodriguez AO; Epstein J; Cress RD
    Gynecol Oncol; 2008 Jan; 108(1):207-13. PubMed ID: 18028989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical factors and biomarkers in ovarian tumors development.
    Vrabie CD; Petrescu A; Waller M; Dina I
    Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second neoplasms after invasive and borderline ovarian cancer.
    Levi F; Randimbison L; Blanc-Moya R; La Vecchia C
    Eur J Cancer Prev; 2009 Jun; 18(3):216-9. PubMed ID: 19491608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. K-ras activation occurs frequently in mucinous adenocarcinomas and rarely in other common epithelial tumors of the human ovary.
    Enomoto T; Weghorst CM; Inoue M; Tanizawa O; Rice JM
    Am J Pathol; 1991 Oct; 139(4):777-85. PubMed ID: 1656759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of reproductive factors, oral contraceptive use and selected lifestyle factors with the risk of ovarian borderline tumors: a Danish case-control study.
    Huusom LD; Frederiksen K; Høgdall EV; Glud E; Christensen L; Høgdall CK; Blaakaer J; Kjaer SK
    Cancer Causes Control; 2006 Aug; 17(6):821-9. PubMed ID: 16783610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival in ovarian cancer patients by histology and family history.
    Ji J; Försti A; Sundquist J; Lenner P; Hemminki K
    Acta Oncol; 2008; 47(6):1133-9. PubMed ID: 18607880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in incidence of and mortality from uterine and ovarian cancer in Mid and South Limburg, The Netherlands, 1986-2003.
    Kellert IM; Botterweck AA; Huveneers JA; Dirx MJ
    Eur J Cancer Prev; 2009 Feb; 18(1):85-9. PubMed ID: 19077569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Childhood and adolescent ovarian malignant tumors in Israel. A nationwide study.
    Menczer J; Sadetzki S; Murad H; Barda G; Andreev H; Barchana M
    Acta Obstet Gynecol Scand; 1999 Oct; 78(9):813-7. PubMed ID: 10535348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer.
    Skírnisdóttir I; Garmo H; Wilander E; Holmberg L
    Int J Cancer; 2008 Oct; 123(8):1897-901. PubMed ID: 18661518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term survival in women with borderline ovarian tumors: a population-based survey of borderline ovarian tumors in Sweden 1960-2007.
    Kalapotharakos G; Högberg T; Bergfeldt K; Borgfeldt C
    Acta Obstet Gynecol Scand; 2016 Apr; 95(4):473-9. PubMed ID: 26714557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone replacement therapy and risk of epithelial ovarian cancer.
    Purdie DM; Bain CJ; Siskind V; Russell P; Hacker NF; Ward BG; Quinn MA; Green AC
    Br J Cancer; 1999 Oct; 81(3):559-63. PubMed ID: 10507786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.